Although BC200 is known to be highly expressed in dendrites and is thought to be involved in local translational regulation [38,39] and BCYRN1 has been shown to be involved in epilepsy, Alzheimer’s disease, and cognitive function of multiple sclerosis [40,41,42], BCYRN1 is known to exhibit high expression in several cancer types, such as non-small-cell lung cancer [43,44,45], gastric cancer [46,47,48], colorectal carcinoma [49,50,51], NK/T-cell lymphoma [52], and glioblastoma [53]. Here, BCYRN1 is linked to early-onset autosomal dominant Alzheimer disease.